I think for a company to make profit in the long run, they have to offer some ongoing therapy plan, as opposed to something that offers a permanent solution like specialized FMTs. I wish more was invested in the latter, as we all know the importance of the microbiome on overall health.
Quite honestly, I have zero hope for the spectrum of new IBD treatments coming out, but I do have hope that some pioneering doctors (like Borody) will find it in themselves to offer tangible and permanent solutions to patients.
"Mongersen was well-tolerated, and toxicities associated with systemically active antisense therapies were not observed."
Great post, so nice to hear about
something without systemic side effects, not listed as a known carcinogen and high remission rate.
From what I read this morning they paid around 700 Million for the rights on a drug that can pull in 3 Billion per year.
I could be wrong and others should check my conclusions from these sources :newdrugapprovals.org/2014/10/22/celgene-oral-crohns-drug-ged-0301-mongersen-impresses-in-phase-ii/www.thestreet.com/story/12919382/1/first-detailed-look-at-celgene-crohns-disease-pill-impresses.html
Just the down payment was 700M, all totaled up could be 2.6B cost. Still profitable from just one years revenue.
"We believe at peak GED-301 [mongersen] could reach $3 billion plus in peak worldwide sales," writes Schoenebaum. "Although sell-side consensus includes very little for the drug, we believe investor expectations are much, much higher than zero. Celgene is planning to start a broad phase 3 program by 2014 year-end, putting a potential launch in the 2017-18 timeframe."
Last April, Celgene purchased mongersen from a small Irish drug maker, paying $710 million upfront. Including future milestones and sales payouts, Celgene committed $2.6 billion to acquire rights to the drug. Celgene was aware of the phase II study data before making the deal.